ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$68.05 USD
+2.17 (3.29%)
Updated May 10, 2024 04:00 PM ET
After-Market: $67.97 -0.08 (-0.12%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
ANIP 68.05 +2.17(3.29%)
Will ANIP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANIP
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for ANIP
ANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue Expectations
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
ANI: Q1 Earnings Snapshot
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
ANI Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY24 outlook